Atacicept Reduces Disease Burden in Lupus Patients with High Disease Activity, Study Shows
Treatment with 150 mg atacicept significantly improves outcomes in systemic lupus erythematosus (SLE) patients with high disease activity, data from a Phase 2b clinical trial show. The results of the trial were presented recently at the 2018 SLEuro Annual Meeting in Dusseldorf, Germany in a poster titled “SRI response,…